Catharine C. Bulik
Research Subjects
Catharine C. Bulik has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Sujata M. Bhavnani
Institute for Clinical Pharmacodynamics (ICPD), 242 Broadway, Schenectady, NY, 12305, USA
3 shared publicationsAlan Forrest
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA
2 shared publicationsChristopher M. Rubino
Institute for Clinical Pharmacodynamics (ICPD), 242 Broadway, Schenectady, NY, 12305, USA
2 shared publicationsJustin C. Bader
Institute for Clinical Pharmacodynamics (ICPD), 242 Broadway, Schenectady, NY, 12305, USA
2 shared publicationsKim L. Sweeney
Institute for Clinical Pharmacodynamics (ICPD), 242 Broadway, Schenectady, NY, 12305, USA
2 shared publicationsLi Zhang
Sanofi, Bridgewater, New Jersey, USA
2 shared publications
Latest Publications
- 14 February 2018
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 45 (2) , 351
Correction to: PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside
The original version of this article contained incorrect Supplementary Files. The correct Supplementary Files are published with this erratum.
- 14 February 2018
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 45 (2) , 351
Correction to: PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside
The original version of this article contained incorrect Supplementary Files. The correct Supplementary Files are published with this erratum.
- 28 March 2017
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 44 (2) , 161-177
PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside
Antimicrobial stewardship programs face many challenges, one of which is a lack of guidance regarding antimicrobial dose, interval, and duration. There is no tool that considers patient demographic, pathogen susceptibility, and pharmacokinetic–pharmacodynamic (PK–PD) targets for efficacy in order to evaluate appropriate antimicrobial dosing regimens. The PK–PD Compass, an educational mobile application, was developed to address this unmet need. The application consists of a Monte Carlo simulation algorithm which integrates pharmacokinetic (PK) and PK–PD data, patient-specific characteristics, and pathogen susceptibility data. Through the integration of these data, the application allows practitioners to assess the percent probability of PK–PD target attainment for 35 intravenous antimicrobial agents across 29 infection categories. Population PK models for each drug were identified, evaluated, and refined as needed. Susceptibility breakpoints were based upon FDA and CLSI criteria. By incorporating these data into one interface, clinicians can select the infection, pathogen, and antimicrobial agents of interest and obtain the percent probability of PK–PD target attainment for each regimen based upon patient-specific characteristics. The antimicrobial dosing regimens provided include those recommended by standard guidelines and reference texts. However, unlike these references, potential choices are prioritized based on percent probabilities of PK–PD target attainment. Such data will educate clinicians on selecting optimized antibiotic regimens through the lens of PK–PD.
- 28 March 2017
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 44 (2) , 161-177
PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside
Antimicrobial stewardship programs face many challenges, one of which is a lack of guidance regarding antimicrobial dose, interval, and duration. There is no tool that considers patient demographic, pathogen susceptibility, and pharmacokinetic–pharmacodynamic (PK–PD) targets for efficacy in order to evaluate appropriate antimicrobial dosing regimens. The PK–PD Compass, an educational mobile application, was developed to address this unmet need. The application consists of a Monte Carlo simulation algorithm which integrates pharmacokinetic (PK) and PK–PD data, patient-specific characteristics, and pathogen susceptibility data. Through the integration of these data, the application allows practitioners to assess the percent probability of PK–PD target attainment for 35 intravenous antimicrobial agents across 29 infection categories. Population PK models for each drug were identified, evaluated, and refined as needed. Susceptibility breakpoints were based upon FDA and CLSI criteria. By incorporating these data into one interface, clinicians can select the infection, pathogen, and antimicrobial agents of interest and obtain the percent probability of PK–PD target attainment for each regimen based upon patient-specific characteristics. The antimicrobial dosing regimens provided include those recommended by standard guidelines and reference texts. However, unlike these references, potential choices are prioritized based on percent probabilities of PK–PD target attainment. Such data will educate clinicians on selecting optimized antibiotic regimens through the lens of PK–PD.
- 1 February 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (2)
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models
Gepotidacin (formerly called GSK2140944) is a novel triazaacenaphthylene bacterial topoisomerase inhibitor with in vitro activity against conventional and biothreat pathogens, including Staphylococcus aureus and Streptococcus pneumoniae . Using neutropenic murine thigh and lung infection models, the pharmacokinetics-pharmacodynamics (PK-PD) of gepotidacin against S. aureus and S. pneumoniae were characterized. Candidate models were fit to single-dose PK data from uninfected mice (for doses of 16 to 128 mg/kg of body weight given subcutaneously [s.c.]). Dose fractionation studies (1 isolate/organism; 2 to 512 mg/kg/day) and dose-ranging studies (5 isolates/organism; 2 to 2,048 mg/kg/day; MIC ranges of 0.5 to 2 mg/liter for S. aureus and 0.125 to 1 mg/liter for S. pneumoniae ) were conducted. The presence of an in vivo postantibiotic effect (PAE) was also evaluated. Relationships between the change from baseline in log 10 CFU at 24 h and the ratio of the free-drug plasma area under the concentration-time curve (AUC) to the MIC (AUC/MIC ratio), the ratio of the maximum concentration of drug in plasma ( C max ) to the MIC ( C max /MIC ratio), and the percentage of a 24-h period that the drug concentration exceeded the MIC (% T >MIC) were evaluated using Hill-type models. Plasma and epithelial lining fluid (ELF) PK data were best fit by a four-compartment model with linear distributional clearances, a capacity-limited clearance, and a first-order absorption rate. The ELF penetration ratio in uninfected mice was 0.65. Since the growth of both organisms was poor in the murine lung infection model, lung efficacy data were not reported. As determined using the murine thigh infection model, the free-drug plasma AUC/MIC ratio was the PK-PD index most closely associated with efficacy ( r 2 = 0.936 and 0.897 for S. aureus and S. pneumoniae , respectively). Median free-drug plasma AUC/MIC ratios of 13.4 and 58.9 for S. aureus , and 7.86 and 16.9 for S. pneumoniae , were associated with net bacterial stasis and a 1-log 10 CFU reduction from baseline, respectively. Dose-independent PAE durations of 3.07 to 12.5 h and 5.25 to 8.46 h were demonstrated for S. aureus and S. pneumoniae , respectively.
- 1 February 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (2)
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models
Gepotidacin (formerly called GSK2140944) is a novel triazaacenaphthylene bacterial topoisomerase inhibitor with in vitro activity against conventional and biothreat pathogens, including Staphylococcus aureus and Streptococcus pneumoniae . Using neutropenic murine thigh and lung infection models, the pharmacokinetics-pharmacodynamics (PK-PD) of gepotidacin against S. aureus and S. pneumoniae were characterized. Candidate models were fit to single-dose PK data from uninfected mice (for doses of 16 to 128 mg/kg of body weight given subcutaneously [s.c.]). Dose fractionation studies (1 isolate/organism; 2 to 512 mg/kg/day) and dose-ranging studies (5 isolates/organism; 2 to 2,048 mg/kg/day; MIC ranges of 0.5 to 2 mg/liter for S. aureus and 0.125 to 1 mg/liter for S. pneumoniae ) were conducted. The presence of an in vivo postantibiotic effect (PAE) was also evaluated. Relationships between the change from baseline in log 10 CFU at 24 h and the ratio of the free-drug plasma area under the concentration-time curve (AUC) to the MIC (AUC/MIC ratio), the ratio of the maximum concentration of drug in plasma ( C max ) to the MIC ( C max /MIC ratio), and the percentage of a 24-h period that the drug concentration exceeded the MIC (% T >MIC) were evaluated using Hill-type models. Plasma and epithelial lining fluid (ELF) PK data were best fit by a four-compartment model with linear distributional clearances, a capacity-limited clearance, and a first-order absorption rate. The ELF penetration ratio in uninfected mice was 0.65. Since the growth of both organisms was poor in the murine lung infection model, lung efficacy data were not reported. As determined using the murine thigh infection model, the free-drug plasma AUC/MIC ratio was the PK-PD index most closely associated with efficacy ( r 2 = 0.936 and 0.897 for S. aureus and S. pneumoniae , respectively). Median free-drug plasma AUC/MIC ratios of 13.4 and 58.9 for S. aureus , and 7.86 and 16.9 for S. pneumoniae , were associated with net bacterial stasis and a 1-log 10 CFU reduction from baseline, respectively. Dose-independent PAE durations of 3.07 to 12.5 h and 5.25 to 8.46 h were demonstrated for S. aureus and S. pneumoniae , respectively.
- 1 November 2013
- Published by Springer Nature
- p. 445-456
Tigecycline
- 1 August 2009
- Vol. 73 (7) , 407-11
Clostridium difficile infection--not just a burden anymore.